Dr. Khan talks about a rare condition called X-Linked Hypophosphatasia (XLH), describing symptoms to look for and how it is transmitted from a parent to a child.
Oct. 23, 2020.
Dr Khan discuss the diagnosis and management of osteoporosis in patients during the COVID19 pandemic at the McMaster university Endocrine Rounds on September 17, 2020.
Dr, Khan discusses the management of Osteoporosis during the COVID19 pandemic alongside a panel of experts.
Presented on June 1, 2020
Dr. Khan’s lecture begins at 40min.
Dr. Khan discusses on how and when to use anabolic therapy at the 8th annual McMaster Day in Endocrinology for Primary Care Providers on October 9th, 2020.
Dr. Khan discusses advances in Hypoparathyroidism at the Henry Ford Health System Grand Rounds on
September 17th, 2020.
Dr Khan discusses updates in the diagnosis and management of Osteoporosis at the Humber River Hospital Family Medicine Rounds on March 4th, 2020.
Dr Khan discusses updates in the diagnosis and management of Hypoparathyroidism for the International Osteoporosis Foundation (IOF) BoneCast Webinar on
Feb 25th, 2020.
EVENITY® is a bone formation humanized monoclonal antibody. It is designed to work by inhibiting the activity of sclerostin, which simultaneously results in increased bone formation and to a lesser extent decreased bone loss.
Dr Khan speaks about a rare metabolic bone disease called X-Linked Hypophosphatemia at the American Society of Bone and Mineral Research (ASBMR) Satellite Symposia in Orlando, Florida.
Dr Khan discusses updates in the diagnosis and management of Hypoparathyroidism at the American Society of Bone and Mineral Research (ASBMR) Satellite Symposia in Orlando, Florida.
Dr Khan and colleagues discuss the burden and clinical presentation of Hypoparathyroidism as well as clinical updates in diagnosis, management, and treatment, and how to translate these strategies into clinical practice.
Dr. Aliya Khan discusses advancements in the management of parathyroid disease at the European Society of Endocrinology Meeting in Turkey.
Dr. Khan provides an update on Guidelines for Primary Hyperparathyroidism – Canadian and International Consensus 2016 in a lecture at McMaster University.
Dr Khan discusses the importance of drug therapy after Health Canada approved PROLIA®, a targeted therapy that treats osteoporosis in postmenopausal women with high-risk fractures.
Dr. Aliya Khan discusses osteoporosis, diagnosis, drug treatments, rehabilitation and exercises.